Wet Macular Degeneration

A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.

Also Known As:

Networked: 18 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Choroidal Neovascularization
2.	Geographic Atrophy
3.	Pterygium
4.	Neoplasms (Cancer)
5.	Macular Degeneration (Age-Related Maculopathy)

Experts

1.	Yee, Wendy: 2 articles (07/2008 - 06/2007)
2.	Bennett, Michael D: 2 articles (07/2008 - 06/2007)
3.	Hu, Zhiwei: 2 articles (01/2007 - 03/2003)
4.	Tezel, Tongalp H: 2 articles (01/2007 - 03/2003)
5.	Garen, Alan: 2 articles (01/2007 - 03/2003)
6.	Kaplan, Henry J: 2 articles (01/2007 - 03/2003)
7.	Kim, Kwang Gi: 1 article (07/2014)
8.	Kim, Young Jae: 1 article (07/2014)
9.	Hwang, Jeong-Min: 1 article (07/2014)
10.	Jeong, Chang Bu: 1 article (07/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Wet Macular Degeneration:

1.	pegaptanibFDA Link 01/01/2006 - "In two controlled, double-blinded identical studies, Macugen 0.3 mg was shown to slow the progression of wet macular degeneration. " 06/01/2007 - "This is the sentinel case of US Food and Drug Administration (FDA) approved pegaptanib usage for non-wet macular degeneration via an Investigational New Drug application (Title 21, Code of Federal Regulations part 132). " 11/01/2005 - "Pegaptanib for wet macular degeneration." 07/01/2008 - "Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration." 07/01/2008 - "To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. "
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/01/2007 - "New medications targeting vascular endothelial growth factor show promise in the treatment of wet macular degeneration. " 01/01/2006 - "Although the cause of wet macular degeneration is not known, it is believed that vascular endothelial growth factor (VEGF) induces angiogenesis, resulting in a neovascular process, the hallmark of wet macular degeneration. " 10/01/2010 - "This year's Lasker DeBakey Clinical Research Award goes to Napoleone Ferrara for the discovery of vascular endothelial growth factor (VEGF) as a major mediator of angiogenesis and for the development of an effective anti-VEGF therapy for wet macular degeneration, a leading cause of blindness in the elderly." 01/01/2008 - "In light of the widespread use of systemic and intraocular anti-VEGF therapies for the treatment of angiogenesis associated with tumor growth and wet macular degeneration, systematic investigation of the role of VEGF in the adult retina is critical. " 01/01/2014 - "Current management of age-related macular degeneration (AMD) can be divided into two categories: first, anti-vasoendothelial growth factor (anti-VEGF) injection for wet macular degeneration; second, anti-oxidant vitamins for dry macular degeneration. "
3.	moxifloxacin (Avelox)FDA Link 07/01/2008 - "Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration." 07/01/2008 - "To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. " 07/01/2008 - "Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration."
4.	Fluorescein (Funduscein)FDA LinkGeneric 01/01/2006 - "Automated change analysis from fluorescein angiograms for monitoring wet macular degeneration." 07/01/2014 - "Fluorescein angiography (FAG) is currently the most useful diagnostic modality for examining retinal circulation, and it is frequently used for the evaluation of patients with diabetic retinopathy, occlusive diseases, such as retinal venous and arterial occlusions, and wet macular degeneration. "
5.	Retinaldehyde (Retinal)IBA 08/01/2007 - "Estimating the potential impact of using intravitreal angiostatic agents for wet macular degeneration on service capacity in a large retinal referral centre." 07/01/2014 - "Fluorescein angiography (FAG) is currently the most useful diagnostic modality for examining retinal circulation, and it is frequently used for the evaluation of patients with diabetic retinopathy, occlusive diseases, such as retinal venous and arterial occlusions, and wet macular degeneration. "
6.	Proton Pump InhibitorsIBA 02/01/2013 - "Five patients with advanced wet macular degeneration described patterned VHs that were induced or enhanced by oral proton pump inhibitors. "
7.	Angiogenesis InhibitorsIBA 08/01/2007 - "Estimating the potential impact of using intravitreal angiostatic agents for wet macular degeneration on service capacity in a large retinal referral centre."
8.	Endothelial Growth FactorsIBA 07/01/2009 - "To describe the use of subconjunctival bevacizumab or ranibizumab, an approved antivascular endothelial growth factor for wet macular degeneration, in halting the inflammation of a pterygium or a partially excised pterygium. "
9.	Interleukin-6 (Interleukin 6)IBA 01/01/2014 - "Aqueous IL-6 may be an important marker of treatment response or resistance in wet macular degeneration. "
10.	Biological Markers (Surrogate Marker)IBA 01/01/2014 - "Evaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration."

Therapies and Procedures

1.	Intravitreal Injections 07/01/2008 - "Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration." 07/01/2008 - "To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. " 07/01/2008 - "Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration."
2.	Immunotherapy 01/01/2007 - "Furthermore, mICON can selectively obliterate already established choroidal neovascularization, which suggests that it may be useful for immunotherapy in patients with exudative (wet) macular degeneration." 03/04/2003 - "Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration."
3.	Lasers (Laser) 03/04/2003 - "Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration."